A plant sterol that blocks some cholesterol absorption in the gut, giving modest "bad" cholesterol lowering and easing urinary symptoms of an enlarged prostate without shrinking it. Other claimed effects are unsettled. An unresolved concern is that absorbed sterol may itself affect the arteries; high absorbers may be better served by other options. (Full Review)

Protocol

Cholesterol dose

~2 g/day plant sterols

Higher doses give little extra LDL benefit while increasing sterol absorption.

Prostate dose

~60–130 mg/day beta-sitosterol

Often standardized plant extracts, over several weeks to months before judging symptom response.

Timing

Split with meals

Must coincide with dietary fat and cholesterol; spread across the largest meals.

Time to effect

Cholesterol onset

2–4 weeks

LDL lowering first appears.

Cholesterol maximal

4–6 weeks

Lipid effect usually at its peak.

Prostate symptoms

4–26 weeks

Urinary symptom improvement emerges in men.

Benefits

High: LDL-cholesterol reduction; improved urinary symptoms in benign prostatic hyperplasia

Medium: Lower total cholesterol and triglycerides

Low: Reduced markers of inflammation; lower dietary cancer risk

Speculative: Metabolic and blood-pressure effects; anti-inflammatory and immune modulation beyond CRP

Contraindications

Sitosterolemia or strong family history (confirmed ABCG5/ABCG8 loss-of-function disorder)

Pregnancy or lactation

Children (only under specialist supervision)

Key Interactions

Cholesterol-absorption drugs (ezetimibe)

Statins (atorvastatin, rosuvastatin, simvastatin)

Bile-acid sequestrants (cholestyramine, colesevelam)

Fat-soluble vitamin and carotenoid supplements (beta-carotene, vitamin E)

Other cholesterol-lowering supplements (red yeast rice, soluble fiber, plant stanols)

Risk & Side Effects

Medium: Reduced absorption of fat-soluble nutrients; atherogenic potential of absorbed sterols

Low: Mild gastrointestinal effects; hormonal effects from 5-alpha-reductase inhibition

Speculative: Accelerated atherosclerosis in susceptible individuals; interference with hormone-sensitive conditions

Monitoring

Marker	Target	Why
LDL-cholesterol	< 100 mg/dL (lower if high cardiovascular risk)	Primary target of the cholesterol effect
Total cholesterol	< 180 mg/dL	Confirms overall lipid response
HDL-cholesterol	> 50 mg/dL (women), > 40 mg/dL (men)	Detects the small HDL rise and overall lipid balance
Triglycerides	< 100 mg/dL	Captures the modest triglyceride reduction
Blood sitosterol / campesterol	As low as feasible; markedly elevated levels are a red flag	Identifies high absorbers at greater cardiovascular risk
International Prostate Symptom Score (IPSS)	Lower score = fewer symptoms (target ≥ 3-point drop)	Tracks the prostate symptom benefit in men

Cadence: Repeat lipid panel at 6–12 weeks, then every 6–12 months; sterol markers as indicated.

Qualitative Assessment

Urinary symptoms: stronger stream, less straining, fewer nighttime trips to the bathroom in men using it for the prostate
General tolerance: absence of persistent digestive upset
Adherence ease: whether taking it with meals fits comfortably into daily routine

Beta-Sitosterol for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment